BRIEF-Astrazeneca Plc Says Imfinzi & Tremelimumab Improved Os In Liver Cancer

AstraZeneca PLC: * ASTRAZENECA PLC - IMFINZI & TREMELIMUMAB IMPROVED OS IN LIVER CANCER * ASTRAZENECA - TRIAL MET PRIMARY ENDPOINT OF OVERALL SURVIVAL WITH A SINGLE PRIMING DOSE OF TREMELIMUMAB PLUS IMFINZI EVERY FOUR WEEKS VERSUS. SORAFENIB * ASTRAZENECA - IMFINZI MONOTHERAPY MET OVERALL SURVIVAL ENDPOINT OF NON-INFERIORITY VERSUS.


Reuters | Updated: 15-10-2021 19:38 IST | Created: 15-10-2021 19:38 IST
BRIEF-Astrazeneca Plc Says Imfinzi & Tremelimumab Improved Os In Liver Cancer

AstraZeneca PLC: * ASTRAZENECA PLC - IMFINZI & TREMELIMUMAB IMPROVED OS IN LIVER CANCER

* ASTRAZENECA - TRIAL MET PRIMARY ENDPOINT OF OVERALL SURVIVAL WITH A SINGLE PRIMING DOSE OF TREMELIMUMAB PLUS IMFINZI EVERY FOUR WEEKS VERSUS. SORAFENIB * ASTRAZENECA - IMFINZI MONOTHERAPY MET OVERALL SURVIVAL ENDPOINT OF NON-INFERIORITY VERSUS. SORAFENIB Source text for Eikon: Further company coverage:

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)

Give Feedback